Sona Nanotech Inc. signs co-marketing agreement with Bond Digital Health
Halifax, Nova Scotia, October 25, 2018 –Sona Nanotech Inc. (CSE: SONA) today announcedit has signed a co-marketing agreement with UK-based digital healthcare company Bond Digital Health.
The agreement means the two companies will work together to market and promote each other’s products and services. For Sona, the agreement will open up a new source of customers and collaborators.
Based in Cardiff, Wales, Bond Digital Health is a software consultancy providing digital solutions and software as a service (SaaS) to the life sciences industry and diagnostic development market. It has created software for a range of life sciences companies including personal diagnostics developer Mologic, for whom its developing an Android app to allow patients to monitor their health outcomes.
Phil Groom, commercial director of Bond Digital Health, said: “We’re very excited to be working with Sona Nanotech, as Sona’s gold nanorod technology is unique and has the potential to transform this market. We can see lots of synergy between our two companies and our products and services, and I’m confident that this agreement will greatly benefit both companies in terms of bringing in new customers, new collaborators and new projects.”
Sona and Bond signed the agreement at a major industry event in San Diego, California, this week. The Advanced Lateral Flow Course 2018 was attended by leading businesses operating in the lateral flow market, including GE Healthcare. Sona Nanotech Inc. was a sponsor of the event, as was Expedeon, with whom Sona recently signed an agreement to supply its gold nanorods
Darren Rowles, CEO of Sona Nanotech, said: “The diagnostic industry is increasing its impact on delivering medical services. Sona’s leading nanoparticle technology allows a growing number of conditions to be monitored and measured. Bond Digital Health’s technology captures data collected with Sona-powered devices and helps patients and medical professionals analyze that data to best support the patient. Partnering Sona with Bond will allow our joint clients not only to collect more data, but to assist medical professionals with how that data can be used to improve the lives of patients. This agreement enhances Sona’s offer, making us a more attractive prospect to lateral flow diagnostic test developers.”
About Sona Nanotech Inc.
Sona Nanotech Inc. is a nanotechnology life sciences firm that has developed two proprietary methods for the manufacture of rod-shaped gold nanoparticles. The principal business carried out and intended to be continued by Sona is the development and application of its proprietary technology for use in multiplex diagnostic testing platforms that will improve performance over existing tests in the market.
Sona’s gold nanorod particles are CTAB (cetyltrimethylammonium) free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona’s gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, pending the approval of various regulatory boards including Health Canada and the FDA.
Sona is a publicly listed company on the Canadian Securities Exchange existing under the laws of Nova Scotia, with its operations in Nova Scotia.
About Bond Digital Health Ltd.
Bond Digital Health Ltd. is a software consultancy developing end-to-end software services for lateral flow assay developers and lateral flow device reader (LFD) manufacturers. Their digital tools enable developers of point of care tests, diagnostics, biosensors and wearable tech to collect and manage their valuable data, so they can refine it for clinical, scientific and commercial gain. Products include: LFD reader data collection apps, cloud-based electronic data capture (EDC), data analysis (AI and machine learning), electronic reported patient outcome apps (ePRO) and data display dashboards.
For More Information
For more information about Sona, please contact:
President and Chief Executive Officer
Telephone: (902) 442-7192
Email: Darren Rowles firstname.lastname@example.orgFORWARD LOOKING INFORMATION
This press release contains forward-looking statements and information that are based on the beliefs of management and reflect the Company’s current expectations. When used in this press release, the words “estimate”, “project”, “belief”, “anticipate”, “intend”, “expect”, “plan”, “predict”, “may” or “should” and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information. The forward-looking statements and information in this press release includes information relating to the Amalgamation (including the structure of the Amalgamation), the Amalgamation (including shareholder approval, shareholder support, and other terms), the Private Placement (including its completion and the use of proceeds from the Private Placement), the directors and management of the resulting issuer upon completion of the Amalgamation, and the implementation of Sona’s business plan. Such statements and information reflect the current view of the Company with respect to risks and uncertainties that may cause actual results to differ materially from those contemplated in those forward-looking statements and information.
By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: risks associated with the completion of the Amalgamation and matters relating thereto; and risks associated with the marketing and sale of securities, the need for additional financing, reliance on key personnel, the potential for conflicts of interest among certain officers or directors, and the volatility of the Company’s common share price and volume. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Investors are cautioned against attributing undue certainty to forward-looking statements.
There are a number of important factors that could cause the Company’s actual results to differ materially from those indicated or implied by forward-looking statements and information. Such factors include, among others, risks related to Sona’s proposed business, such as failure of the business strategy and government regulation; risks related to Sona’s operations, such as additional financing requirements and access to capital, reliance on key and qualified personnel, insurance, competition, intellectual property and reliable supply chains; risks related to Sona and its business generally, such as infringement of intellectual property rights and conflicts of interest. The Company cautions that the foregoing list of material factors is not exhaustive. When relying on the Company’s forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. The Company has assumed a certain progression, which may not be realized. It has also assumed that the material factors referred to in the previous paragraph will not cause such forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors. While the Company may elect to, it does not undertake to update this information at any particular time.
THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS PRESS RELEASE REPRESENTS THE EXPECTATIONS OF THE COMPANY AS OF THE DATE OF THIS PRESS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD-LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE. WHILE THE COMPANY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE LAWS